logo

For the Inventor, By the Inventor

Shrewsbury, MA, United States of America

John C Fann

This inventor holds 11 USPTO granted patents and 4 published patent applications. Top assignees: Abbvie Inc., Abbott Laboratories Corporation, Other. Active years: 2012-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John C Fann. Retrieved from https://idiyas.com/inventor/john-c-fann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 81.8

Average Co-Inventor Count = 7.8

ph-index = 8

Forward Citations = 303(Granted Patents)


Company Filing History:

goldMedal9 out of 826 
 
Abbvie Inc.
 patents
silverMedal1 out of 4,188 
 
Abbott Laboratories Corporation
 patents
bronzeMedal1 out of 834,513 
Other
 patents

Years Active: 2012-2018

Loading Chart...
11 patents (USPTO):Explore Patents
1. 10119118 - Modified serum-free cell culture medium (2018-11-06),
2. 9416181 - Compositions for cell culture and methods of using the same (2016-08-16),
3. 9284371 - Methods of producing adalimumab (2016-03-15),
4. 9234032 - Fed-batch methods for producing adalimumab (2016-01-12),
5. 9090867 - Fed-batch method of making anti-TNF-alpha antibody (2015-07-28),
6. 9073988 - Fed batch method of making anti-TNF-alpha antibodies (2015-07-07),
7. 9068970 - Efficient and effective supplement screening for the development of chemically defined media in cell culture (2015-06-30),
8. 8911964 - Fed-batch method of making human anti-TNF-alpha antibody (2014-12-16),
9. 8906646 - Fed-batch method of making human anti-TNF-alpha antibody (2014-12-09),
10. 8663945 - Methods of producing anti-TNF-alpha antibodies in mammalian cell culture (2014-03-04),
11. 8093045 - Fed-batch cell culture methods using non-animal-based hydrolysates (2012-01-10),

Title: John C. Fann: Innovator in Cell Culture Technology

Introduction

John C. Fann is a notable inventor based in Shrewsbury, MA (US), recognized for his contributions to the field of cell culture technology. With a total of 11 patents to his name, Fann has made significant advancements that enhance the production of recombinant proteins, particularly antibodies.

Latest Patents

Fann's latest patents include innovative methods and compositions for producing recombinant proteins in mammalian cell culture. One of his key inventions is a modified serum-free cell culture medium, which describes improved methods for producing antibodies. This invention provides enhanced cell culture media, including production media and feed solutions, aimed at improving protein productivity. Another notable patent focuses on the supplementation of bioflavonoids, such as epigallocatechin gallate and rutin, into mammalian cell culture media. This approach effectively reduces acidic species variants in recombinant antibodies, leading to a less heterogeneous product with potential improvements in antibody structure and function.

Career Highlights

Throughout his career, John C. Fann has worked with prominent companies in the biotechnology sector, including AbbVie Inc. and Abbott Laboratories Corporation. His work in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in the field.

Collaborations

Fann has collaborated with several professionals in his field, including Itzcoatl A. Pla and Christof Schulz. These collaborations have further enriched his research and development efforts, leading to impactful innovations.

Conclusion

John C. Fann's contributions to cell culture technology and his impressive portfolio of patents underscore his role as a leading inventor in the biotechnology industry. His work continues to influence the production of recombinant proteins, paving the way for advancements in therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…